It’s best to be first, but drugs that are approved later with the same mechanism of action can also create significant value for patients and society by being best-in-class (BIC), or what clinicians refer to as “gold standard.” Recently we highlighted key factors that can make a follow-on drug be considered a best-in-class drug. This article provides ten historical case studies of best-in-class drug strategies across therapeutic indications.
Case Studies of Best-in-Class (BIC) Drugs:
The following case studies (1-3 for therapeutic superiority, 4-6 for improved safety and 7-10 for improving patient acceptance/lowering treatment burden) explore in more detail how a drug can create more value to become considered best-in-class:
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
